Health Care & Life Sciences » Biotechnology | 22nd Century Group Inc.

22nd Century Group Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
26,153.20
15,595.40
11,031.90
11,581.40
13,029.10
7,966.90
Depreciation, Depletion & Amortization
144.30
462.80
774.30
842.20
947.00
1,342.30
Other Funds
3,232.10
3.50
46.10
-
-
11,668.40
Funds from Operations
4,357.10
6,100.00
6,590.70
9,472.40
11,366.70
18,292.90
Changes in Working Capital
501.30
482.70
731.10
415.20
701.60
448.70
Net Operating Cash Flow
3,855.80
6,582.70
7,321.80
9,887.60
12,068.40
17,844.30
Capital Expenditures
3,742.80
2,389.50
450.70
553.80
1,607.10
Sale of Fixed Assets & Businesses
-
631.50
-
-
-
Purchase/Sale of Investments
-
700.00
-
-
58,979.10
Net Investing Cash Flow
3,742.80
2,708.00
450.70
553.80
60,586.20
Issuance/Reduction of Debt, Net
1,809.50
-
508.30
333.30
333.30
Net Financing Cash Flow
5,717.40
9,862.80
5,130.10
20,149.20
62,846.00
Net Change in Cash
5,830.40
572.10
2,642.40
9,707.90
9,808.70
Free Cash Flow
403.40
6,795.20
7,359.30
10,084.80
13,225.30
Net Assets from Acquisitions
-
250.00
-
-
-
Change in Capital Stock
4,294.90
9,859.30
5,592.30
20,482.60
63,179.30

About 22nd Century Group

View Profile
Address
8560 Main Street
Clarence New York 14221
United States
Employees -
Website http://www.xxiicentury.com
Updated 07/08/2019
22nd Century Group, Inc. is a plant biotechnology company, which engages in the development of technology that will allow to increase or decrease the level of nicotine and nicotinic alkaloids in tobacco plants and levels of cannabinoids in cannabis plants through genetic engineering and plant breeding. Its products include X-22, modified risk cigarettes, spectrum government research cigarettes, magic 0 and magic 2, moonlight, red sun, variable nicotine-level research cigarettes, and verfola. The company was founded on January 25, 2011 and is headquartered in Clarence, NY.